ReShape Lifesciences, Inc.

As of August 16, 2021, ReShape Lifesciences, Inc. is considered a risky investment due to its negative financial metrics, including a Price to Book Value of 2.51, an EV to EBITDA of -0.09, a Return on Equity of -501.25%, and a year-to-date stock return of -98.52%, significantly underperforming the S&P 500.

As of August 16, 2021, ReShape Lifesciences, Inc. is considered overvalued and rated as "risky" due to negative financial metrics, including a P/E ratio that is not applicable, a price-to-book value of 2.51, an EV to EBITDA ratio of -0.09, and a severely low ROE of -501.25%, which are worse than its peers.

As of May 27, 2025, the market trend is mildly bearish, influenced by daily moving averages and Bollinger Bands, despite some mixed signals from weekly indicators like MACD and RSI.

As of March 2022, the management team of ReShape Lifesciences, Inc. includes Kim Kamdar (Independent Chairman), Andrew Rasdal (CEO), William Plovanic, Raymond Dittamore, Douglas Fisher, and Lesley Howe (all Independent Directors). They oversee the company's strategic direction and operations.

ReShape Lifesciences, Inc. is a medical device company focused on obesity treatment, with recent net sales and profit of $1 million each. It has a market cap of $6.37 million and operates at a loss, reflected in its negative P/E and return on equity metrics.

As of Jun 18, ReShape Lifesciences, Inc. has a market capitalization of 6.37 million, with net sales of 7.17 million and a net profit of -3.46 million over the last four quarters. The company reported shareholder's funds of -0.25 million and total assets of 4.83 million as of Dec 24.